블로그

HIV

IVIG for HIV Infection: Providing Immune Support for HIV Patients

Doctor consulting with patient about IVIG for HIV

In the United States, there are roughly 1.2 million HIV-positive people, and about 36,136 new HIV diagnoses were made in 2022, according to a CDC report. 

IVIG 공제금 지원 받기

IVIG 재정 지원
(877) 778-0318

HIV infection weakens the immune system and makes a person’s body more vulnerable to other infections. Over time, HIV infection progresses into its potentially serious life-threatening stage called AIDS (acquired immunodeficiency syndrome).

Though there is no cure for HIV, effective treatments like antiretroviral therapy and IVIG 치료 can help to stop the progression of the disease and boost immunity in HIV patients. 

This article discusses the basics of HIV, how it affects your immune system, and how IVIG therapy can help. 

What Is HIV Infection?

HIV (human immunodeficiency virus) is an infection caused by the HIV virus. This virus is transmitted to your body through sexual intercourse (unprotected) or by using HIV-contaminated needles. Once inside the body, HIV remains there for a lifetime. 

How Does HIV Affect Your Immune System?

Once HIV enters your body, it affects your immune system in the following ways:

It Destroys CD4 Helper T Cells

HIV attacks and destroys specific types of immune cells called CD4 helper cells or T cells, which generally help your body fight infection or illness. Without HIV treatment, minor ailments such as colds can be much more severe.  

Furthermore, when the number of CD4 helper cells falls below 200 cells/mm3 or when people develop one or more opportunistic infections, it leads to a serious stage of HIV called AIDS (acquired immunodeficiency syndrome). 

It Impairs B Cells’ Functions

Apart from directly destroying CD4 helper T cells, HIV also indirectly impairs the function of B cells. Normally, CD4 T cells activate B cells to produce antibodies against the virus. However, when HIV destroys the CD4 cells, the B cells fail to mount a strong antibody immune response. 

HIV also hyperactivates and exhausts the B cells, which results in the production of ineffective and poor-quality antibodies that are unable to cope with the HIV infection. Over time, the antibodies’ quality and specificity begin to decline, further contributing to weakening the immune response. 

Hence, during HIV infection, the virus not only directly destroys the CD4 helper T cells but also indirectly impairs the function of B cells. 

IVIG 복용량을 받으세요

재택 주입
상담 일정을 잡으세요

How Can IVIG Help HIV Patients?

Intravenous immunoglobulin (IVIG) therapy works to boost the immune system in the patient’s body by providing a broad spectrum of antibodies. In fact, various reports have shown that receiving IVIG therapy could be beneficial for HIV patients. 

Doctor holding red ribbon for HIV awareness

IVIG and HIV Patients

Though the exact mechanism of IVIG is not clear, this therapy can help HIV patients in the following ways:

It Provides Additional Immune Support

The antibodies provided by IVIG do not kill the virus but provide additional immune support to HIV patients to fight infections they are prone to. Since HIV patients have weak immune systems, they are more susceptible to opportunistic bacterial and viral infections such as respiratory infections. 

The FDA has also approved the use of IVIG therapy to reduce the risk of serious bacterial infections in children with HIV. For example, a study conducted on HIV-infected children with recurrent infections and some HIV-infected adults showed that IVIG reduces the risk of bacterial infection in these patients. Similarly, another 공부하다 of symptomatic HIV-infected children showed that IVIG decreases the incidence of respiratory infections and mortality in children. 

It Increases the Level of CD4 and CD8 Cells

IVIG therapy also increases the level of CD4 and CD8 cells in HIV patients. For example, in a case report of an HIV-1 positive patient with Guillain-Barre Syndrome (GBS), IVIG treatment increased the level of CD4 and CD8 cell counts and decreased the plasma viral load. 

It Reduces Inflammation in HIV Patients

IVIG therapy has anti-inflammatory properties. Patients with HIV often experience chronic inflammation, which further damages their immune systems. The anti-inflammatory effect of IVIG can help reduce inflammation and slow down the progression of HIV in patients. 

요약

IVIG therapy can be a beneficial option for HIV patients. IVIG not only boosts immunity but also reduces the risks of bacterial infections and inflammation and increases the CD4 cell count in patients. It is recommended to consult your doctor before undergoing IVIG treatment to get the best results.

참고문헌:

  1. Yap, P., & Williams, P. (1988). The treatment of human immunodeficiency virus-infected patients with intravenous immunoglobulin. Journal of Hospital Infection, 12, 35-46. https://doi.org/10.1016/0195-6701(88)90028-X
  2. Yap, P. L. (1994). Does intravenous immune globulin have a role in HIV-infected patients? 임상 및 실험 면역학, 97(Suppl 1), 59-67. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550376/
  3. Nicholas, K. J., Zern, E. K., Barnett, L., Smith, R. M., Lorey, S. L., Copeland, C. A., Sadagopal, S., & Kalams, S. A. (2013). B Cell Responses to HIV Antigen Are a Potent Correlate of Viremia in HIV-1 Infection and Improve with PD-1 Blockade. PLOS ONE, 8(12), e84185. https://doi.org/10.1371/journal.pone.0084185
  4. Rosca, E. C., Rosca, O., & Simu, M. (2015). Intravenous immunoglobulin treatment in a HIV-1 positive patient with Guillain-Barré syndrome. International Immunopharmacology, 29(2), 964-965. https://doi.org/10.1016/j.intimp.2015.09.023
  5. Pastori, D., Esposito, A., & Mezzaroma, I. (2010). Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review. International Reviews of Immunology, 30(1), 44–66. https://doi.org/10.3109/08830185.2010.529975
  6. Mofenson, L. M., Bethel, J., Moye Jr, J., Flyer, P., & Nugent, R. (1993). Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. JAIDS Journal of Acquired Immune Deficiency Syndromes, 6(10), 1103-1113.
  7. Yap, P. L., M. Todd, A. A., Williams, P. E., Hague, R. A., Mok, J., Burns, S. M., & Brettle, R. P. (1991). Use of intravenous immunoglobulin in acquired immune deficiency syndrome. , 68(S6), 1440-1450. https://doi.org/10.1002/1097-0142(19910915)68:6+<1440::AID-CNCR2820681407>3.0.CO;2-Y
  8. Gor, D., Singh, V., Gupta, V., & Levitt, M. (2022). A persistent parvovirus infection causing anemia in an HIV patient requiring intravenous immunoglobulin maintenance therapy. Curēus. https://doi.org/10.7759/cureus.24627
  9. Mofenson, L. M., & Moye, J. (1993). Intravenous Immune Globulin for the Prevention of Infections in Children with Symptomatic Human Immunodeficiency Virus Infection. Pediatric Research, 33(4), S80-S89. https://doi.org/10.1203/00006450-199304001-00015
이 정보는 의학적 조언이나 치료를 대체할 수 없습니다. 새로운 치료를 시작하기 전에 담당 의사 또는 의료 서비스 제공자와 건강 상태에 대해 상담하십시오. AmeriPharma® Specialty Care는 제공된 정보 또는 그 결과로 내려진 진단이나 치료에 대해 어떠한 책임도 지지 않으며, 콘텐츠의 신뢰성에 대해서도 책임을 지지 않습니다. AmeriPharma® Specialty Care는 여기에 나열된 모든 웹사이트/기관을 운영하는 것은 아니며, 해당 콘텐츠의 가용성이나 신뢰성에 대해서도 책임을 지지 않습니다. 이러한 목록은 AmeriPharma® Specialty Care의 보증, 후원 또는 추천을 암시하거나 구성하지 않습니다. 이 웹페이지에는 AmeriPharma® Specialty Care와 제휴하지 않은 제약 회사의 상표 또는 등록 상표인 브랜드 처방약에 대한 참조가 포함될 수 있습니다.
Dr. Mark Alfonso
의학적으로 검토됨 마크 알폰소 박사, 약학박사, BCMTMS

마크 알폰소 약학박사는 콜로라도주 푸에블로에서 태어나고 자랐습니다. 그는 2010년 콜로라도 대학교 약학대학 앤슈츠 의대에서 약학 학위를 받았습니다. 2022년에는 약물 치료 관리 전문 자격증을 취득했습니다. 그의 업무에서 가장 보람 있는 부분은 환자의 질문과 우려 사항에 답변하는 것입니다. 그의 전문 분야는 지역 약국과 약물 치료 관리입니다. 여가 시간에는 독서와 달리기를 즐깁니다.

문의하기

아래 HIPAA 규격 양식을 사용하여 처방전 재조제를 요청하세요. 복용 중인 약이나 복용 방법에 대한 문의 사항이 있으시면 문의하기 페이지를 방문하시거나 다음 번호로 전화해 주세요. (877) 778-0318.

HIPAA Compliant

제출하면 AmeriPharma에 동의하는 것입니다. 이용 약관, 개인정보 보호정책, 그리고 개인정보 보호 관행 고지

ko_KRKorean